INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1480
PATAU SYNDROME: A MOLECULAR ANALYSIS
Muminov Ilyosbek Oʻrinboy oʻgʻli
Namangan State University
Raximjonova Rayxona Axmadjon qizi
Abstract:
Patau syndrome (Trisomy 13) is a severe chromosomal disorder caused by the
presence of an extra copy of chromosome 13. It is characterized by multiple congenital
anomalies, severe intellectual disability, and a high mortality rate. This article presents a
molecular overview of the syndrome, highlighting the genetic mechanisms, diagnostic
approaches, and implications for prenatal screening and therapeutic research.
Keywords
: Patau syndrome, Trisomy 13, molecular genetics, prenatal diagnosis, chromosomal
abnormalities.
Introduction
Patau syndrome, also known as Trisomy 13, is a rare but devastating chromosomal
condition resulting from the presence of an additional chromosome 13. First described by Klaus
Patau in 1960, the syndrome has an incidence of approximately 1 in 10,000 to 1 in 16,000 live
births. The condition is often associated with severe malformations of the central nervous
system, heart defects, cleft lip/palate, and polydactyly.
Due to the high genetic load imposed by the trisomy, more than 90% of affected infants
do not survive past the first year. While clinical manifestations have been well documented, the
molecular basis and chromosomal mechanisms require deeper investigation for improved
diagnostic and therapeutic strategies.
Materials and Methods
A comprehensive literature review was conducted using PubMed, ScienceDirect, and
Google Scholar databases focusing on studies published between 2000 and 2024. Molecular
diagnostic tools evaluated include fluorescence in situ hybridization (FISH), quantitative PCR,
array comparative genomic hybridization (aCGH), and next-generation sequencing (NGS).
Case studies and reviews related to prenatal diagnosis and gene expression in Trisomy 13 were
also examined.
Results
1. Chromosomal Origin
Approximately 75% of Patau syndrome cases result from nondisjunction during
maternal meiosis, leading to full trisomy 13. A smaller percentage is due to mosaicism or
Robertsonian translocations involving chromosome 13.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1481
2. Gene Dosage Effects
The extra copy of chromosome 13 leads to the overexpression of multiple genes
involved in cell signaling, apoptosis, and neural development. Genes such as
SHH (Sonic
Hedgehog)
, located on 7q36 but interacting with 13q pathways, are implicated in the
craniofacial and brain abnormalities observed in Trisomy 13.
3. Molecular Diagnostic Tools
Modern tools such as
aCGH
and
NGS
enable rapid and accurate detection of
chromosomal duplications and deletions. FISH and quantitative PCR are commonly used for
confirming suspected cases in prenatal and postnatal settings.
Discussion
The molecular characterization of Patau syndrome has revealed that gene dosage
imbalance caused by trisomy 13 disrupts normal embryonic development. Although the exact
genotype-phenotype correlation remains complex due to genetic heterogeneity and possible
epigenetic modifications, advances in molecular diagnostics have improved early detection.
Prenatal screening through
non-invasive prenatal testing (NIPT)
and confirmatory
molecular karyotyping allows for early diagnosis, helping families make informed decisions.
Research into the transcriptomic and proteomic changes in Trisomy 13 continues to open doors
for understanding developmental pathways affected by the disorder.
Despite these advances, therapeutic options remain limited, with most management
approaches focusing on palliative care. Future research may investigate gene expression
modulators or RNA-based interventions to mitigate the severity of certain phenotypes.
Conclusion
Patau syndrome remains one of the most severe chromosomal disorders, and its
molecular analysis provides valuable insights into the effects of gene dosage and chromosomal
imbalance. Continued research into the genetic and epigenetic mechanisms underlying Trisomy
13 is essential for improving diagnostic precision and exploring potential therapeutic avenues.
References:
1. Patau, K. et al. (1960). Multiple congenital anomaly caused by an extra chromosome.
Lancet, 275(7128), 790-793.
2. Carey, J. C. (2012). Trisomy 13 and 18 and genetic counseling in a new era. American
Journal of Medical Genetics Part C, 160C(3), 166–174.
3. McGowan-Jordan, J. et al. (2016). ISCN 2016: An International System for Human
Cytogenomic Nomenclature.
4.
Bianchi, D. W., & Wilkins-Haug, L. (2014). Integration of noninvasive DNA testing for
aneuploidy into prenatal care. Obstetrics and Gynecology, 124(3), 715–721.
